SignalChem Lifesciences Corporation

December 04, 2014 09:00 ET

SignalChem Initiates Phase 1 Clinical Trial for SLC-0111 in Solid Tumours

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Dec. 4, 2014) - SignalChem Lifesciences Corp. ("SLC"), has dosed its first patient in a Phase 1a clinical trial studying the safety and tolerability of SLC-0111. The study marks a significant clinical milestone for SLC. Taking a personalized medicine approach, the Company is developing SLC-0111 for the targeted treatment of various forms of cancer.

SLC-0111 is a proprietary small molecule that selectively targets CAIX enzyme within the hypoxic regions of the tumour. Hypoxic areas of tumours host aggressive cancer cells that are resistant to conventional therapies and CAIX plays a critical role in their survival. No drug therapies currently exist for blocking CAIX enzyme activity in hypoxic areas of solid tumours. "There is currently a significant unmet need for a treatment that could decrease the survival of cancer cells in the hypoxic regions of a tumour, said Jasbinder Sanghera, PhD., CEO of SLC. "Targeting the CAIX enzyme represents a promising new approach for treating and preventing tumour growth, especially recurrence, and SLC is the first company that has demonstrated success in reaching these difficult areas of the tumour. This therapy could provide a meaningful benefit to cancer patients."

The initiation of clinical development for SLC-0111 follows extensive research and preclinical studies where the compound demonstrated consistently positive effects for the treatment of various tumours. "Our studies have demonstrated that SLC-0111 may work well in effectively stopping and shrinking various tumours, prevent recurrence, metastases, and cancer stem cell survival, commented Dr. Shoukat Dedhar, one of the original developers of the program, distinguished scientist and the Professor of the Department of Integrative Oncology, BC Cancer Research Centre and University of British Columbia. "This program may prove to be a major step forward in treating both tumour growth and spread in a segment of the tumour, which if left untreated, has a devastating impact on patients."

SLC is also developing a backup small molecule inhibitor of CAIX (SLC-021) and in collaboration with the National Research Council of Canada, a monoclonal antibody (SLC-0131) targeting CAIX. Both programs are in the preclinical development stage.

About the Phase 1 Trial

The Phase 1a trial is a dose escalation study and the Company will enroll up to 30 cancer patients with refractory solid tumours. The study is being conducted by Ozmosis Research Inc., Toronto, ON with sites located at The Princess Margaret in Toronto, Ontario, the Cross Cancer Institute in Edmonton, Alberta and the BC Cancer Agency in Vancouver, BC. The primary objective is to investigate the safety and tolerability of SLC-0111. The company plans to start Phase 1b studies later in 2015. These trials will involve selecting patients whose tumours express CAIX and treating only these patients with SLC-0111.

About CAIX

SLC has identified and validated the metalloenzyme Carbonic Anhydrase IX (CAIX), which is expressed selectively on the cell surface of hypoxic (oxygen depleted) tumour cells particularly cancer stem cells, and is one of the major factors contributing to cancer cell survival and metastasis. The role of CAIX is to catalyse the reversible hydration of carbon dioxide to bicarbonate and protons: H2O + CO2 to HCO3- + H+

About SLC

SignalChem Lifesciences ("SLC") discovers and develops drug candidates using a personalized medicine approach. We identify patients with a specific kinase defect and then select a relevant targeted therapy against the defective kinase. SLC's development process selects the most relevant kinase targets for drug development and identifies the best compound from our kinase specific chemical library. This ensures best-in-class potency and superior selectivity; yielding highly effective drug candidates with greatly reduced side effects. Our approach has the potential to provide a much more effective therapy and allows SLC to apply the therapy to only those patients who are most likely to receive a meaningful clinical benefit. For more information please visit

Forward-Looking Statements and Information

This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied. Readers are cautioned not to place undue reliance on such forward-looking statements.

Contact Information